Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
About this study
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
- Condition
- Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
- Tested
- DCC-2812
- Sponsor
- Deciphera Pharmaceuticals, LLC
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 18 years
- Study condition: Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
- Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
- Able to take oral medication
- If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
- Adequate organ function and electrolytes
Exclusion 3
- Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
- Impaired cardiac function
- Major surgery within 28 days of the first dose of study drug
Where
8 sites, 8 recruiting
University of Michigan
Ann Arbor, Michigan, United States
NEXT Oncology, Austin
Austin, Texas, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Cleveland Clinic
Cleveland, Ohio, United States
Vanderbilt- Ingram Cancer Center
Nashville, Tennessee, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
and 2 more sites on ClinicalTrials.gov
Contact
-
Clinical Team
888-724-3274 clinicaltrials@deciphera.com
Potential match only. Final eligibility is determined by the study team.